Cargando…
Cellular photo(geno)toxicity of gefitinib after biotransformation
Gefitinib (GFT) is a selective epidermal growth factor receptor (EGFR) inhibitor clinically used for the treatment of patients with non-small cell lung cancer. Bioactivation by mainly Phase I hepatic metabolism leads to chemically reactive metabolites such as O-Demethyl gefitinib (DMT-GFT), 4-Defluo...
Autores principales: | El Ouardi, Meryem, Tamarit, Lorena, Vayá, Ignacio, Miranda, Miguel A., Andreu, Inmaculada |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10283009/ https://www.ncbi.nlm.nih.gov/pubmed/37351506 http://dx.doi.org/10.3389/fphar.2023.1208075 |
Ejemplares similares
-
Photoprocesses of the tyrosine kinase inhibitor gefitinib: from femtoseconds to microseconds and from solution to cells
por: Tamarit, Lorena, et al.
Publicado: (2021) -
Switching from ultrafast electron transfer to proton transfer in excited drug–protein complexes upon biotransformation
por: Tamarit, Lorena, et al.
Publicado: (2022) -
Protein Binding of Lapatinib and Its N- and O-Dealkylated Metabolites Interrogated by Fluorescence, Ultrafast Spectroscopy and Molecular Dynamics Simulations
por: Andreu, Inmaculada, et al.
Publicado: (2020) -
ArrhythmoGenoPharmacoTherapy
por: Tosaki, Arpad
Publicado: (2020) -
ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC
por: Zhao, Hongbo, et al.
Publicado: (2018)